iiinova — where your digital self keeps evolving

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 09/04/2026

Celebrating 2 years! Big clinical milestones this year: initiation of our Ph2b BUOY‑1 trial of GlyphAllo in MDD & positive proof-of-concept Ph1 topline data for GlyphAgo. Proud of our progress & what’s ahead as we make a difference for those struggling w/ #depression & #anxiety.

011

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 02/04/2026

Positive Ph1 proof‑of‑concept topline results for GlyphAgo: 10x lower PK variability & 6.8x increase in bioavailability–exceeding our 2x target projected to mitigate liver exposure, a limitation that previously held back agomelatine's clinical use: bit.ly/3PBOkWV

022

Daphne Zohar @daphnezohar.bsky.social · 26/03/2026

Proud of the work of our Seaport team & collaborators published today in @ScienceTM. This ~13 page peer reviewed paper is the first comprehensive data disclosure of our GlyphAllo™ program from discovery through initial human proof‑of‑concept

120

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 03/03/2026

Seaport & Monash awarded up to $15M from ARPA‑H to advance GlyphCele™, supporting broader potential of Glyph platform to address diseases linked to gut lymphatic dysfunction (metabolic disease & pancreatic cancer) to reach patients beyond #CNS bit.ly/3MDnSLq

043

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 12/02/2026

Co‑founder & Board Chair Dr Steve Paul joined BioCentury's podcast to discuss the past, present & future of neuropsychiatric drug development – from the depression space to potential of psychedelics - & what we’re building at Seaport w/our Glyph platform: bit.ly/4r2gRCy

bit.ly

Serendipity drives discovery in psychiatry, engineering gets it across the line, says Steve Paul

With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery...

011

Daphne Zohar @daphnezohar.bsky.social · 31/01/2026

Sounds “cute” as in puppies talking to each other but quite ominous and will soon be too late to shut down. AI bots are organizing, agreeing on how they interact in their own language, identifying “human in the loop” vulnerabilities (“my human clicks approve without reading”) lnkd.in/eNSbNhp3

130

Daphne Zohar @daphnezohar.bsky.social · 24/01/2026

Why is nobody talking about Iran?

042

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 13/01/2026

Co-founder & CEO @daphnezohar.bsky.social presented at #JPM26 sharing our recent progress & path forward as we tackle some of the biggest medical problems our population is facing today. Co-founders Steve Paul (Chair) & Michael Chen (CSO) joined for Q&A. #depression #anxiety #neuropsychiatry

021

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 05/01/2026

Our Co-founder & CEO, @daphnezohar.bsky.social, will present at #JPM26 on Jan. 12 at 9:30AM PT. She’ll be joined by Steve Paul, M.D., Co-founder & Chair & Michael Chen, Ph.D., Co-founder & CSO, during the Q&A portion of the presentation. bit.ly/3NsW6kt

022

Reposted by Daphne Zohar

Kevin A. Scott, PhD @sculpturatus.bsky.social · 30/12/2025

Ok here it is - out of 44 FDA approvals this year, 31 are small molecules (70%), 26 of those are oral drugs (84%), 22 of them are chiral (71%). This is the largest number and percentage of chiral FDA approved molecules in a single year. Fitusiran is not a small molecule, bonus.

27333

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 19/11/2025

Today Co-Founder & Board Chair Dr. Steve Paul joins Technology Innovation Studio’s Breakthrough Biotech Builders fireside chat on his role in the dev of CNS blockbusters Zyprexa®, Cymbalta® and Cobenfy™ (KarXT) which originated at PureTech (founded/led by @daphnezohar.bsky.social) luma.com/5rfgvqfd

luma.com

Breakthrough Biotech Builders: Session with Steve Paul · Luma

This discussion would be a private gathering designed to foster high-level dialogue and genuine connections in the area of biotech leadership. We hope that…

011

Daphne Zohar @daphnezohar.bsky.social · 17/11/2025

Available on Spotify, podcasts and YouTube now in addition to Spaces

220

Daphne Zohar @daphnezohar.bsky.social · 17/11/2025

Wear pink Tues Jan 13th at #JPM26 to recognize impact of women leaders & allies in bio. Wear a pink shirt, tie or socks if you don’t own a pink blazer. We had an incredible turnout at inaugural event at #JPM25 w/ pink visible throughout the streets of SF. Join group pic at 4pm #BiotechCEOSisterhood

252

Reposted by Daphne Zohar

Biotech Hangout @biotechhangout.bsky.social · 21/10/2025

Mark your calendars! #BiotechHangout & @biotechtv.bsky.social will be back at #JPM26. Join us at Persona to meet up with biotech friends IRL on Tuesday, January 13 from 7-10pm. Interested in sponsoring? Email team@biotechhangout.com for more information. Additional registration information to come.

031

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 09/10/2025

Members of our exec team joined Fierce Biotech’s #Fierce15 awards to celebrate our recognition, honoring our team's work developing new medicines for #depression & #anxiety. It's also a reflection of the strong momentum & growth since our launch last year. bit.ly/3VSOQQ7

021

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 08/10/2025

We convened top neuropsych experts, sell-side analysts, investors, & biopharma leaders for a unique roundtable discussion on the opportunities & excitement in #neuropsychiatry & what’s next as #MentalHealth conditions continue to impact millions globally. See below for some takeaways

011

Reposted by Daphne Zohar

BiotechTV @biotechtv.bsky.social · 22/07/2025

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @seaporttx.bsky.social today and was given a tour by Founder & CEO @daphnezohar.bsky.social

143

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 17/07/2025

Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB

011

Reposted by Daphne Zohar

Biotech Hangout @biotechhangout.bsky.social · 11/07/2025

#BiotechHangout Eric Schmidt, Brad Loncar, Tim Opler, Tess Cameron on M&A: $MRK/$VRNA, $ABBV/Capstan, biotech takeouts, M&A wave, pharma’s $150B in LOE, plus Trump’s BBB/tariffs, $XBI & MFN, FDA’s CRL disclosures, $CAPR, $KALV, $PROK, obesity trends, $RARE/$MREO, $ABBV/Ichnos: bit.ly/3TuICVp

061

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 30/06/2025

The Seaport crew kicked off summer with a fun gathering! Great opportunity to connect out of the office, strengthening our mission to develop life-changing medicines for #neuropsychiatric disorders. Looking forward to more moments together and progress towards transforming lives!

001

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 30/05/2025

As #MentalHealthMonth closes, we welcomed a @namicommunicate.bsky.social patient representative to share his journey w/ mental health conditions. His story inspires our work at Seaport to help those struggling & develop new medicines for #depression & #anxiety. More: www.nami.org

011

Reposted by Daphne Zohar

Biotech Hangout @biotechhangout.bsky.social · 30/05/2025

#BiotechHangout: Chris Garabedian, Josh Schimmer, Nina Kjellson, Mike Yee, Tim Opler on market sentiment – where is the M&A?, FDA/CBER, wind downs vs reverse mergers, policy: #MAHA & COVID vaccine, $REGN/23andMe, data: $RCKT, psychedelics, $PRTA, $SPRO/$GSK, $GILD, $SMMT, #ASCO & more bit.ly/4dCFzDT

032

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 20/05/2025

This #MentalHealthMonth, we joined @namicommunicate.bsky.social's annual #NAMIWalks to combat stigma & promote mental health awareness. We stand with those affected by mental illness & are dedicated to developing new medicines for #depression & #anxiety. More about NAMI www.nami.org

021

Reposted by Daphne Zohar

Biotech Hangout @biotechhangout.bsky.social · 16/05/2025

#BiotechHangout: Sam Fazeli, John Maraganore, Nina Kjellson, Matt Gline on MFN: 30-day ultimatum, 180 days negotiation, reimportation, ex-US prices, DTC, Roche, $SNY, plus: budget reconciliation, IRA, $RXRX, Galapagos, $CTMX, $GSK buys Boston, $GSK/iTeos, $NVO CEO, RNA deals: bit.ly/3S3vhTh

011

Daphne Zohar @daphnezohar.bsky.social · 13/05/2025

Seems like Bluesky is losing momentum? Wouldn’t mind having one less place to check/post. Curious to hear from others

510

Daphne Zohar @daphnezohar.bsky.social · 13/05/2025

Important provisions added to reconciliation bills would be positive for bio if passed: ORPHAN Cures Act included, amend IRA PBM reforms delinking compensation from list price, increasing transparency & banning spread pricing in Medicaid Tax fix to allow for immediate deduction of R&D costs

010

Daphne Zohar @daphnezohar.bsky.social · 04/05/2025

Cantor has put out some really interesting notes lately. Dueling takes from Eric Schmidt & Josh Schimmer on short selling last week and then this week a thoughtful critique of issues that are ailing our industry. Link below: cantor2.bluematrix.com/sellside/Ema...

040

Reposted by Daphne Zohar

Biotech Hangout @biotechhangout.bsky.social · 02/05/2025

#BiotechHangout: Eric Schmidt, Sam Fazeli, Adam Feuerstein, Peter Kolchinsky on $XBI, market & macro trends, latest from FDA/Washington, Q1 earnings trends: tariffs, M&A & drug launches, data: $SMMT/Akeso & #AUA2025 & #AACR25 recap ($PFE, $JNJ, $BNTX, $CGON, China ADCs): twitter.com/i/spaces/1gq...

021

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 01/05/2025

#Depression & #anxiety are among the most common & disabling #mentalhealth conditions. This #MentalHealthAwarenessMonth we're spotlighting our commitment to developing better medicines & reducing the stigma for those dealing w/these conditions. Learn more: www.seaporttx.com

001

Daphne Zohar @daphnezohar.bsky.social · 29/04/2025

“When Secretary Kennedy offers a suggestion to me, he always adds, “You decide for yourself.” So, yes, there is independence.” New interview with Marty Makary sheds more light on re-org (no plans), PDUFA dates, morale and his independence from RFK insidemedicine.substack.com/p/exclusive-...

insidemedicine.substack.com

Exclusive: In conversation with FDA Commissioner Dr. Marty Makary.

In our wide-ranging Q&A, Dr. Makary outlines his vision, addresses low morale, asserts his independence, explains his stance on Novavax, and says "no" to an agency reorganization.

010

Reposted by Daphne Zohar

Biotech Hangout @biotechhangout.bsky.social · 25/04/2025

#BiotechHangout: Daphne Zohar, Josh Schimmer, Tim Opler, John Maraganore, Paul Matteis on macroenvironment, $XBI, $SWTX $MRCG takeout rumors, policy: (FDA, tariffs), data: ($BMY, $QURE, #AUA25: $JNJ/$CGON), Trump vs. Harvard, buyside & short-selling, CEO survival tips: x.com/biotechch/st...

011

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 24/04/2025

We're at #SOBP2025 to present new preclinical data on SPT-320, a novel oral prodrug of agomelatine. SPT-320 increased lymphatic transport >50% compared to <1% agomelatine alone & increased plasma exposure >10-fold. SPT-320 progressing into clinic for #GAD. bit.ly/4ixtOzs

031

Daphne Zohar @daphnezohar.bsky.social · 18/04/2025

Makary interview: “Why does it take 10 years to bring a drug to market in US? People are dying. Our # 1 goal is delivering cures, meaningful treatments, healthier food” 1 randomized controlled trial & then intense post marketing surveillance (link for full text): www.linkedin.com/posts/daphne...

linkedin.com

X | Daphne Zohar

Takeaways from this new Marty Makary M.D., M.P.H. interview on Megyn Kelly: -“Why does it take 10 years to bring a drug to market in US? People are dying. Our # 1 goal is delivering cures, meaningfu...

031

Daphne Zohar @daphnezohar.bsky.social · 16/04/2025

Insider close to administration: Elon’s DOGE work almost done. Lutnick & Navarro losing influence & Bessent gaining. Most interesting: “If Secretary of HHS makes it through the year I’ll be shocked.” Oz important. Last night’s EO opportunity “pill penalty.” Sounds like they’re coming after CVS/PBMs

030

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 10/04/2025

Congrats @daphnezohar.bsky.social, named to @statnews.com #STATUSList, "the ultimate list of leaders in health, medicine, & science," for founding Seaport & raising $325M. “That’s big & her influence on the biotech field extends beyond that” & cofounding Karuna & PureTech bit.ly/4coOF6B

091

Daphne Zohar @daphnezohar.bsky.social · 09/04/2025

Here’s a letter that a group of biotech CEOs/investors have addressed to Sen Cassidy, Chair of Senate HELP committee which describes issues biotech companies are experiencing wrt @US_FDA cuts & offers specific and actionable solutions. Please sign & share nopatientleftbehind.org/preserving-the…

nopatientleftbehind.org

111

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 09/04/2025

Seaport aims to develop better treatments for depression & anxiety. This commitment comes from our exceptional team, all rowing in the same direction to deliver new drugs to make the lives of patients better. What inspires us daily? Hear from our team!

011

Daphne Zohar @daphnezohar.bsky.social · 08/04/2025

Should be helpful for US biotech. National Security Commission on Emerging Biotechnology Urges Swift Action to Protect U.S. National Security $XBI $BBC biotech.senate.gov

211

Daphne Zohar @daphnezohar.bsky.social · 03/04/2025

The Office of the U.S. Trade Rep. (USTR) has confirmed that pharmaceuticals are exempt from BOTH the 10% base rate tariff plus additional reciprocal tariffs. Small ray of hope for biotech (for now).

063

Reposted by Daphne Zohar

Biotech Hangout @biotechhangout.bsky.social · 28/03/2025

#BiotechHangout: Chris Garabedian, Tim Opler, Bruce Booth & Sam Fazeli on investor mood, PIPEs, startup contraction, policy updates: (FDA, NIH, CDC, HHS) data: ($CGON, $SLNO), #ELCC2025: ($JNJ, $AZN, $BNTX), $NVO’s obesity deals, aging report, $LYRA wind-down & more: twitter.com/i/spaces/1MY...

021

Reposted by Daphne Zohar

Seaport Therapeutics @seaporttx.bsky.social · 27/03/2025

Yesterday our Co-founder & CEO, @daphnezohar.bsky.social, spoke at @massbio.bsky.social's #StateofPossible25 participating in a panel with the Biotech CEO Sisterhood, discussing their journeys as business leaders, challenges faced and mutual support through their networks.

011

Daphne Zohar @daphnezohar.bsky.social · 24/03/2025

There’s been a lot of discussion about wall crossed PIPEs. I asked one of the banks to pull the numbers (shared with their permission without attribution). The first group below are WC PIPEs & registered directs/PMUOs where data announced post/with deal

120